Development of a single item patient reported measure of treatment side effect burden in clinical trials of rheumatic and musculoskeletal diseases using stakeholder input and large language model refinement

By afschroeder • June 28, 2026

Berthelsen DB, Horgan B, Simon L, Ioannidis JPA, Goel N, Tugwell P, Balay-Dustrude E, Bartlett SJ, Bingham CO, Boers M, Bouillot C, Böhm P, Choy E, Cowern M, Dagsvik K, Djurtoft C, Furst DE, Haugegaard T, Hazlewood GS, Hoens AM, Jørgensen TS, Kelly SE, Kruzikas D, Musaus J, Richards P, Shea BJ, Strand V, Thomas M, Torralba K, Voshaar M, Weinbrecht-Mischkewitz M, Woodworth TG, Wright G, Flurey C, Christensen R; OMERACT Safety Working Group. Development of a single‑item patient‑reported measure of treatment side‑effect burden in clinical trials of rheumatic and musculoskeletal diseases using stakeholder input and large language model refinement. Semin Arthritis Rheum. 2026 Jun 19;79:153026. doi: 10.1016/j.semarthrit.2026.153026. Epub ahead of print. PMID: 42364594.

Tags: Adverse events, Core outcome set, Harms, Large language model, OMERACT, Publications, Rheumatology, rheumatology, safety

Effects of Age on Inflammatory Bowel Disease Presentation and Management in Older Adults

Sisliyan C, Andres JT, Keyashian K. Effects of Age on Inflammatory Bowel Disease Presentation and Management in Older Adults. Dig Dis Sci. 2026 Aug 9.[...]

Staff Perspectives on Optimising Organisational Responses to Patient-Initiated Workplace Violence

Cannedy S, Lesser R, Yano EM, Hamilton AB, Fenwick KM. Staff Perspectives on Optimising Organisational Responses to Patient-Initiated Workplace Violence. J Adv Nurs. 2026 Aug[...]

Effectiveness and safety of rituximab-pvvr versus originator rituximab for rheumatoid arthritis in the veterans health administration

Ghassemi S, Singh JA, Jiang R, Young-Xu Y, Cunningham FE, Glassman PA, Zhao X, Salone C, Au A, Miller DR, Her Q, Dong D, Aspinall[...]